



Jack Brennan, Ph.D.

Principal
New York
212 765 5070
brennan@fr.com

Overview

Jack Brennan, Ph.D., focuses his practice on patent prosecution, opinions, due diligence, and client counseling in the fields of biotechnology and pharmaceuticals.

Jack advises clients of all sizes and at every stage, from startup companies to large multinational pharmaceutical and biotech corporations. His experience includes protein-based products, antibodies, mRNA-based products and other nucleic acids, and a variety of other biotech- and pharma-related innovations.

Clients appreciate Jack's clarity, diligence, focus, and guidance that enable them to build strong patent portfolios. He carefully scrutinizes his clients' programs, gains a clear understanding of their aspirations, and then drafts claims to ensure the protection needed, optimize the patent's enforceability, and advises on avoiding infringing others' patents. Clients often call on him to conduct due diligence investigations, and he frequently prepares freedom-to-operate, patentability, and infringement opinions.

Jack thrives on a challenge and enjoys complex problem-solving. He has lectured extensively on patent term adjustment, an area of law he helped develop via multiple successful challenges to the U.S. Patent and Trademark Office's methodology for calculating patent term adjustment.

In graduate school, Jack conducted doctoral research in genetics that involved identification and characterization of cell surface receptors used by natural killer cells to identify target cells.

A leader in his field, Jack has been listed in *IAM Patent 1000: The World's Leading Patent Professionals* (2013-2022).

**Admitted only in Massachusetts. Not admitted to practice in New York. Work conducted in New York is directly supervised by a member of the New York bar or is limited to U.S. federal courts and agencies listed in admissions or otherwise authorized by law.*

Recognitions & awards

IAM Patent 1000

IAM2013-2025

Insights

Blog | January 23, 2014

Federal Circuit Decision on Patent Term Adjustment

Article | December 20, 2013

Timing of PTO Disclosures - A Trap for the Unwary

News

News | May 30, 2025

Fish & Richardson Receives Top Rankings in 2025 Edition of *IAM Patent 1000: The World's Leading Patent Professionals*

News | June 11, 2024

Fish & Richardson Receives Top Rankings in 2024 Edition of *IAM Patent 1000: The World's Leading Patent Professionals*

News | June 27, 2023

Fish & Richardson Receives Top Rankings in 2023 Edition of *IAM Patent 1000: The World's Leading Patent Professionals*

News | September 8, 2022

Fish & Richardson Receives Top Rankings in 2022 Edition of *IAM Patent 1000: The World's Leading Patent Professionals*

News | July 7, 2021

Fish & Richardson Receives Top Rankings in 2021 Edition of *IAM Patent 1000: The World's Leading Patent Professionals*

News | August 12, 2020

Fish & Richardson Receives Top "Gold" Ranking from *IAM Patent 1000* for National Litigation Practice; National Rankings in the Plaintiff Firm and Prosecution...

News | June 20, 2019

Fish & Richardson Receives Top "Gold" Ranking from *IAM Patent 1000* for National Patent Litigation Practice

News | June 14, 2018

Fish Receives Top "Gold" Ranking from *IAM Patent 1000* for National Patent Litigation Practice

News | July 24, 2017

Fish & Richardson Receives Top "Gold" Ranking from *IAM Patent 1000* for National Patent Litigation Practice

News | June 15, 2016

Fish & Richardson Named to *IAMPatent 1000* for National Patent Litigation and Prosecution Practices

Media Coverage | September 21, 2012

Patent Term Adjustment: The New USPTO Rules

Fish & Richardson

News | February 23, 2010

USPTO Acknowledges Miscalculation in Patent Term Adjustment

Additional insights

Publications

- "Adjusting the life of a US patent due to Patent Office delay," co-author, *Industrial Biotechnology* (February 2010), 6(1): 18-21.
 - Brennan "A state based right to physician assisted suicide," *B.U.L. Rev.* 79:231 (1999).
 - Brennan, et al. "Heterogeneity among Ly-49C natural killer (NK) cells: Characterization of highly related receptors with differing functions and expression patterns," *J. Exp. Med.* 184:2085 (1996).
 - Brennan, et al. "Recognition of class I major histocompatibility complex molecules by Ly-49: specificities and domain interactions," *J. Exp. Med.* 183:1553 (1996).
 - Brennan, et al. "Carbohydrate recognition by a natural killer cell receptor, Ly-49C," *J. Biol. Chem.* 270:9691 (1995).
 - Brennan, *et al.* "Expression of different members of the Ly-49 gene family defines distinct natural killer cell subsets and cell adhesion properties," *J. Exp. Med.* 180:2287 (1994).
-

Services

Patent
Patent Prosecution
Strategic Patent Counseling & Opinions
Patent Portfolio Management

Industries

Life Sciences
Biotech & Diagnostics
Pharmaceuticals

Admissions

U.S. Patent and Trademark Office (2001)
Massachusetts (1999)

Education

J.D. *magna cum laude*, Boston University School of Law (1999) Member, Boston University Law Review
Ph.D., Genetics, University of British Columbia (1996)
B.S., Biology, University of Dayton (1990)